CA2725154A1 - Methods of treatment utilizing binding proteins of the interleukin-21 receptor - Google Patents

Methods of treatment utilizing binding proteins of the interleukin-21 receptor Download PDF

Info

Publication number
CA2725154A1
CA2725154A1 CA2725154A CA2725154A CA2725154A1 CA 2725154 A1 CA2725154 A1 CA 2725154A1 CA 2725154 A CA2725154 A CA 2725154A CA 2725154 A CA2725154 A CA 2725154A CA 2725154 A1 CA2725154 A1 CA 2725154A1
Authority
CA
Canada
Prior art keywords
antigen
binding protein
binding
human
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2725154A
Other languages
English (en)
French (fr)
Inventor
Laird Bloom
Davinder Gill
Yulia Vugmeyster
Deborah A. Young
Margot O'toole
Heath M. Guay
Karissa K. Adkins
Amy Arlene Weaver
Sadhana Jain
Maya Arai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CA2725154A1 publication Critical patent/CA2725154A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
CA2725154A 2008-05-23 2009-05-26 Methods of treatment utilizing binding proteins of the interleukin-21 receptor Abandoned CA2725154A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5554308P 2008-05-23 2008-05-23
US61/055,543 2008-05-23
US9947608P 2008-09-23 2008-09-23
US61/099,476 2008-09-23
PCT/US2009/045188 WO2009143526A1 (en) 2008-05-23 2009-05-26 Methods of treatment utilizing binding proteins of the interleukin-21 receptor

Publications (1)

Publication Number Publication Date
CA2725154A1 true CA2725154A1 (en) 2009-11-26

Family

ID=41092124

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2725154A Abandoned CA2725154A1 (en) 2008-05-23 2009-05-26 Methods of treatment utilizing binding proteins of the interleukin-21 receptor

Country Status (13)

Country Link
US (2) US8178097B2 (cg-RX-API-DMAC7.html)
EP (1) EP2296689A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520989A (cg-RX-API-DMAC7.html)
KR (1) KR20110021919A (cg-RX-API-DMAC7.html)
CN (1) CN102149403A (cg-RX-API-DMAC7.html)
AR (1) AR072136A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009248812A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912998A2 (cg-RX-API-DMAC7.html)
CA (1) CA2725154A1 (cg-RX-API-DMAC7.html)
IL (1) IL209455A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010012812A (cg-RX-API-DMAC7.html)
RU (1) RU2010152689A (cg-RX-API-DMAC7.html)
WO (1) WO2009143526A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
KR20130011056A (ko) * 2011-07-20 2013-01-30 주식회사에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
CN102532320A (zh) * 2012-03-06 2012-07-04 中国药科大学 全人源的抗人白介素21受体的单链抗体及其应用
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2019160978A1 (en) * 2018-02-13 2019-08-22 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
KR102255964B1 (ko) * 2018-11-19 2021-05-24 한국생명공학연구원 신규한 il-15-il-21 융합 폴리펩티드 및 이의 용도
WO2021023108A1 (zh) * 2019-08-02 2021-02-11 正大天晴康方(上海)生物医药科技有限公司 一种抗pd-1抗体及其医药用途
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE60036930T2 (de) 1999-03-09 2008-10-09 Zymogenetics, Inc., Seattle Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
AU5142300A (en) 1999-05-18 2000-12-05 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
CA2420992C (en) * 2000-04-05 2010-07-13 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
JP2004500845A (ja) 2000-05-11 2004-01-15 ジェネティクス　インスティテュート，エルエルシー サイトカインレセプターファミリーのメンバーであるｍｕ−１
WO2003040313A2 (en) * 2001-11-05 2003-05-15 Zymogenetics, Inc Il-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
EP1531850B1 (en) * 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
JP4776228B2 (ja) * 2002-07-15 2011-09-21 ワイス・エルエルシー Ｔヘルパー（ｔｈ）細胞の発生および機能を調節するための方法および組成物
US7495085B2 (en) 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
ZA200507235B (en) 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
AU2004275871A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
CA2566333A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
KR20070057789A (ko) * 2004-08-05 2007-06-07 와이어쓰 인터루킨-21 수용체 활성의 상쇄
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
BRPI0912998A2 (pt) 2015-10-13
RU2010152689A (ru) 2012-06-27
IL209455A0 (en) 2011-01-31
US8178097B2 (en) 2012-05-15
CN102149403A (zh) 2011-08-10
AR072136A1 (es) 2010-08-11
US20090298081A1 (en) 2009-12-03
US20120276102A1 (en) 2012-11-01
AU2009248812A1 (en) 2009-11-26
MX2010012812A (es) 2011-01-21
EP2296689A1 (en) 2011-03-23
JP2011520989A (ja) 2011-07-21
WO2009143526A1 (en) 2009-11-26
KR20110021919A (ko) 2011-03-04

Similar Documents

Publication Publication Date Title
US8178097B2 (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
EP3299392B1 (en) Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
KR101605908B1 (ko) Ｃｄ154에 특이적으로 결합하는, 항체, 항체 유도체 및 항체 단편을 포함하는 결합 단백질, 및 그의 용도
CA2643226C (en) Antibodies against human il-22 and uses therefor
KR20190028534A (ko) 항 gprc5d 항체, gprc5d 및 cd3에 결합하는 이중특이성 항원 결합 분자, 및 이들의 용도
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
JP2009528288A (ja) ヒトｉｌ−２２に対する抗体の使用方法
US20120264919A1 (en) Interleukin-21 receptor binding proteins
KR20210049128A (ko) 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도
WO2022258015A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
KR20250139415A (ko) 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
HK1157220A (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
KR102903323B1 (ko) 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK1157358A (en) Interleukin-21 receptor binding proteins
MXPA05003949A (es) Fragmentos fab de anticuerpo completamente humano con actividad neutralizadora de interferon-gamma humano.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131218